IL33 and acute lymphoblastic leukemia: In addition, identifying specific inhibitors of IL-33/p38 MAPK/AKT pathway in conjunction with other therapies, such as chemotherapy, targeted therapies, and immunotherapy, may be further investigated so as to broaden the horizon of the biology of IL-33 in ALL.